Lidocaine vaginal - Enhance Pharmaceuticals

Drug Profile

Lidocaine vaginal - Enhance Pharmaceuticals

Latest Information Update: 24 Apr 2007

Price : $50

At a glance

  • Originator Enhance Pharmaceuticals
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
  • Mechanism of Action Cell membrane permeability inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anaesthesia

Most Recent Events

  • 24 Apr 2007 Discontinued - Preclinical for Anaesthesia in USA (Vaginal)
  • 17 Jun 2002 Enhance Pharmaceuticals has been acquired by Barr Laboratories
  • 28 Mar 2002 Barr Laboratories expects to acquire Enhance, subject to conditions, by June 30, 2002
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top